Here are the 10-K annual reports from Biohaven Ltd. (BHVN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BHVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHVN filings page.
Biohaven Ltd. is a biopharmaceutical company focused on immunology, neuroscience, and oncology, highlighting a shift toward three late-stage “key programs.” These include the IgG degrader BHV-1300 for Graves’ disease and other autoimmune conditions, the TRAP degrader BHV-1400 for IgA nephropathy, and the Kv7 activator opakalim for epilepsy.
The report describes strong Phase 1 data for BHV-1300 and BHV-1400 and plans to start pivotal trials for Graves’ disease and IgA nephropathy in 2026. It also outlines the myostatin inhibitor taldefgrobep alfa in obesity and spinal muscular atrophy, and extensive work on the glutamate modulator troriluzole in spinocerebellar ataxia. However, the FDA issued a Complete Response Letter for the SCA New Drug Application, taldefgrobep did not meet the primary endpoint in spinal muscular atrophy, and opakalim failed primary endpoints in major depressive disorder and bipolar disorder, underscoring regulatory and clinical risk.